# Zydus Lifesciences Ltd (ZYDUSLIFE)
> Exchange: NSE | Sector: Pharma | ISIN: 

## Price
Current Price: ₹1038.95
Day Change: +0.24%
52W High: ₹1059
52W Low: ₹835.85
Market Cap: ₹1,01,755 Cr

## Valuation
P/E: 20.62
P/B: 4.02
EPS: ₹49.05
Book Value: ₹251.49
Dividend Yield: 0%

## Returns
1Y Return: 6.36%

## Profitability
ROE: 0%
ROCE: 22.11%
Debt/Equity: 0.34
Revenue Growth: 30.3%
Profit Growth: 1.9%
EBITDA Margin: 27.89%
Operating Margin: 18.83%

## About
Zydus is a leading Indian company in the Pharmaceuticals space, listed on the NSE. The company is a key player in the Pharma — Formulations segment with a strong market position and diversified operations.
Sector: Pharma
Industry: Drug Manufacturers - Specialty & Generic
Sub Industry: Pharma — Formulations

## Business Model
Overview: Zydus Lifesciences Ltd makes money through Core Business, Other Segments, Exports in Pharma — Formulations. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Source: Derived from stock data
Revenue Streams:
- Core Business
- Other Segments
- Exports
Operating Model:
- Develops, manufactures, distributes, or services healthcare products across regulated channels.
- Approvals, product mix, compliance quality, and R&D productivity shape growth.
Business Segments:
- Core Business: 70% of tracked revenue, equal to ₹20,955 Cr. | 70% | ₹20,955 Cr
- Other Segments: 35% of tracked revenue, equal to ₹10,478 Cr. | 35% | ₹10,478 Cr
- Exports: -5% of tracked revenue, equal to ₹-1,497 Cr. | -5% | ₹-1,497 Cr
Recent Context:
- Announcement: Corporate Action-Updates on Buy back
- Announcement: Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- BSE Filing: Announcement under Regulation 30 (LODR)-Acquisition

## Access
Current tier: anonymous
More history: Register free to see 9 more years.

## Data Freshness
Quote Updated: 2026-05-24T20:00:16.442Z
Price History Updated: 2026-05-17T21:29:51.401Z
Latest Price History Date: 2026-05-17
Technicals Updated: 2026-05-17T21:29:51.401Z
Quant Updated: 2026-05-17T21:29:51.401Z
Sentiment Updated: 2026-05-17T21:29:51.401Z
Financials Status: current
Financials Updated: 2026-05-18T02:53:19.445Z
Financials Last Attempt: 2026-05-18T02:53:19.445Z
Financials Provider Tried: yahoo
Latest P&L Period: FY25
Latest Balance Sheet Period: FY25
Latest Cash Flow Period: FY25

## P&L (Mar 2015)
Revenue: ₹7224 Cr
Operating Profit: ₹1203 Cr (OPM 17%)
Net Profit: ₹836 Cr
Tax: ₹942 Cr

## Annual P&L History
Mar 2015: Rev ₹7224Cr | PAT ₹836Cr | OPM 17%
Mar 2016: Rev ₹8651Cr | PAT ₹1188Cr | OPM 20%
Mar 2017: Rev ₹9427Cr | PAT ₹1964Cr | OPM 25%

## Balance Sheet (Mar 2015)
Total Assets: ₹7986 Cr
Total Liabilities: ₹7986 Cr
Borrowings: ₹2700 Cr
Cash: ₹undefined Cr

## Shareholding
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%

## Board
- Sharvil Pankajbhai Patel, MD & Executive Director
- Punit  Patel, President & CEO of America
- Tushar Dhansukh Shroff, President of Finance & CFO
- Arvind  Bothra, Head of Investor Relations
- Dhaval Narendra Soni, Company Secretary & Compliance Officer

## Highlights
- Strong revenue growth of 11% CAGR over 5 years
- ROE of 15.0% indicates efficient capital allocation

## Concerns
- Debt-to-equity ratio needs monitoring amid expansion plans
- Promoter holding has seen slight decline in recent quarters

---
Source: rupiya.io/stocks/zyduslife
Disclaimer: For research and education only. Not investment advice.